122 related articles for article (PubMed ID: 11079279)
1. Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae.
Kays MB; Conklin M
Pharmacotherapy; 2000 Nov; 20(11):1310-7. PubMed ID: 11079279
[TBL] [Abstract][Full Text] [Related]
2. Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model.
Hershberger E; Rybak MJ
Antimicrob Agents Chemother; 2000 Mar; 44(3):598-601. PubMed ID: 10681324
[TBL] [Abstract][Full Text] [Related]
3. Broth microdilution and E-test for determining fluoroquinolone activity against Streptococcus pneumoniae.
Kays MB; Graff MA
Ann Pharmacother; 2002 Mar; 36(3):416-22. PubMed ID: 11895052
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana.
Kays MB; Denys GA
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):193-8. PubMed ID: 11576793
[TBL] [Abstract][Full Text] [Related]
5. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
6. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Coyle EA; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2001 Jun; 45(6):1654-9. PubMed ID: 11353608
[TBL] [Abstract][Full Text] [Related]
7. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.
Peterson ML; Hovde LB; Wright DH; Hoang AD; Raddatz JK; Boysen PJ; Rotschafer JC
Antimicrob Agents Chemother; 1999 Sep; 43(9):2251-5. PubMed ID: 10471574
[TBL] [Abstract][Full Text] [Related]
8. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.
Jorgensen JH; Weigel LM; Swenson JM; Whitney CG; Ferraro MJ; Tenover FC
Antimicrob Agents Chemother; 2000 Nov; 44(11):2962-8. PubMed ID: 11036007
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
Frei CR; Burgess DS
Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
[TBL] [Abstract][Full Text] [Related]
10. The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
Ebisu H; Kishii R; Takei M; Fukuda H
J Infect Chemother; 2003 Sep; 9(3):210-4. PubMed ID: 14513387
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
[TBL] [Abstract][Full Text] [Related]
12. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
Evans ME
Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
[TBL] [Abstract][Full Text] [Related]
14. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model.
Lister PD; Sanders CC
Antimicrob Agents Chemother; 1999 May; 43(5):1118-23. PubMed ID: 10223923
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins.
Brisse S; Milatovic D; Fluit AC; Verhoef J; Martin N; Scheuring S; Köhrer K; Schmitz FJ
Antimicrob Agents Chemother; 1999 Aug; 43(8):2051-5. PubMed ID: 10428935
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Bauernfeind A
J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
[TBL] [Abstract][Full Text] [Related]
18. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.
Jones RN; Rubino CM; Bhavnani SM; Ambrose PG;
Antimicrob Agents Chemother; 2003 Jan; 47(1):292-6. PubMed ID: 12499204
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of fluoroquinolones (gatifloxacin, levofloxacin and trovafloxacin) and seven other antibiotics against Streptococcus pneumoniae.
Nicodemo AC; Mendes CM; Oplustil CP; Sinto S
Braz J Infect Dis; 2001 Apr; 5(2):50-2. PubMed ID: 11493408
[TBL] [Abstract][Full Text] [Related]
20. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae.
Ambrose PG; Grasela DM
Diagn Microbiol Infect Dis; 2000 Nov; 38(3):151-7. PubMed ID: 11109013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
